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Introduction
TNF receptor-associated periodic syndrome (TRAPS) is
an autoinflammatory disease causing unprovoked fevers,
myalgia, abdominal pain, rash, headaches, and, in severe
cases, AA amyloidosis. It is an autosomal dominant con-
dition resulting from variants in the TNF super family
receptor 1A (TNFRSF1A) gene [1]. A hallmark of TRAPS
is a huge activation of the inflammatory response in the
absence of autoantibodies or antigen-specific T-cells [1].
Canakinumab (CAN) is a high-affinity, fully human,
selective, anti-IL-1b monoclonal antibody, developed for
the treatment of autoinflammatory diseases [2].
Objectives
To determine whether gene expression in whole blood
can support a molecular mechanism for the activity of
CAN in TRAPS patients (pts).
Methods
Twenty pts with active TRAPS received open-label CAN
150mg sc/month for 4 months in an efficacy and safety
study. These pts were assessed at Day 15 for response
by physician global assessment (PGA) disease activity
scale. Whole blood was collected at baseline, Day 15
and Day 113 from 19 of these pts and 1 sample each
from 19 untreated age-matched healthy volunteers for
analysis of gene expression levels by microarrays.
Results
All 20 pts showed improvements in PGA score. Gene
expression profiles of these pts were altered by treatment
with CAN. Forty-six differentially expressed genes
showed a >2-fold change after treatment with expression
levels that shifted towards that of healthy volunteers. The
disease-causing gene, TNFRSF1A,, drug target gene, IL-1b,
and other inflammation related genes (e.g., MAPK14) were
downregulated after treatment and several inflammation
related pathways were evident among the differentially
expressed genes. Many of the high confidence differen-
tially expressed genes had expression levels that correlated
with neutrophil count, however, neutrophil count alone
could not account for the expression differences observed.
Conclusion
Altogether, the gene expression data support a model in
which CAN increases neutrophil apoptosis and reduces
pro-inflammatory signals through its inhibition of IL-1b.
CAN is able to reverse the overexpression of several
genes associated with inflammatory response, including
IL-1. Interestingly, IL-1 blockade normalized the overex-
pression of the disease-causing gene, TNFRSF1A, at the
RNA level, suggesting a direct impact on the main
pathogenic mechanism of TRAPS.
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